Goldman Sachs says this little-known biotech stock can double on potentially ‘blockbuster’ revenue

Goldman Sachs says this little-known biotech stock can double on potentially ‘blockbuster’ revenue

The firm expects a study on the company’s treatment for obesity will yield positive results.

Posted in Uncategorized.